SPY423.22+2.36 0.56%
DIA339.66+0.88 0.26%
IXIC14,254.38+112.90 0.80%

Revance Therapeutics Q1 EPS $(1.08) Beats $(1.09) Estimate, Sales $13.30M Beat $10.98M Estimate

Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.09) by 0.92 percent. This is a 6.09 percent increase over losses of $(1.15) per share

05/10/2021 16:58
Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.09) by 0.92 percent. This is a 6.09 percent increase over losses of $(1.15) per share from the same period last year. The company reported quarterly sales of $13.30 million which beat the analyst consensus estimate of $10.98 million by 21.12 percent. This is a 22.83K percent increase over sales of $58.00 thousand the same period last year.